Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million October 6, 2026
AstraZeneca, Daiichi Sankyo, and Summit Therapeutics to evaluate Datroway + ivonescimab combo across multiple tumour types October 6, 2026
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences October 6, 2026
United Immunity Announces Master Clinical Supply Agreement with Roche to Evaluate UI-102 + Anti–PD-L1 Therapy in Advanced Solid Tumors October 6, 2026
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma October 6, 2026
Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs October 6, 2026
Earendil Labs Announces Research Collaboration with Genentech to Discover and Develop Therapeutic Bispecific Antibodies in Oncology October 1, 2026
AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance ADC combination strategy in cancer October 1, 2026
Henlius and Amberstone Partner to Develop Next-Generation Conditionally Activated TCEs for Solid Tumours October 1, 2026
InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines October 1, 2026
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015 October 1, 2026
$92.5M Series E Financing to Advance First-in-class Cyclin D1 Program CID-615 into Clinical Development Announced September 22, 2026
Circle Pharma Announces $92.5 Million Series E Financing to Advance First-in-class Cyclin D1 Program into Clinical Development September 22, 2026
NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Ph 2a Results September 22, 2026
Ratio Therapeutics Enters into Research Collaboration and License Agreement with RayzeBio to Advance a Novel Radiopharmaceutical Program September 16, 2026
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda in FAP-α Positive Solid Tumors September 16, 2026
Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy September 16, 2026
First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology September 16, 2026
